FEB 24, 2019 07:30 PM PST

Possible Therapeutic for Duchenne Muscular Dystrophy (DMD)

WRITTEN BY: Nouran Amin

Individuals diagnosed with Duchenne muscular dystrophy (DMD) face few treatment options. DMD is a progressive muscle weakness and degeneration with loss of contractibility caused by one of several mutations in the DMD gene that leads to the chronic activation of a transcription factor called NF-κB—leading to the loss of the dystrophin protein in muscle cells.

DMD affects 3,500-6,000 male births and is the most common genetic neuromuscular disease. It is caused by one of several mutations in the DMD gene. No matter what the particular mutation, a key driver of muscle degeneration and suppression of muscle regeneration in DMD is chronic activation of the transcription factor NF-κB, which causes loss of dystrophin, a protein which helps keep muscle cells intact. Current therapeutics either assist only a subset of DMD patients who have a particular genetic mutation or cause significant side effects.

Learn more about Duchenne Muscular Dystrophy (DMD):

However, a recent investigational drug called ‘edasalonexent’, an oral NF-κB inhibitor, may hold the potential to slow the progression of the disease. The drug was recently examined to hold no safety issues during a Phase I clinical trial. Paving the way for more clinical testing, results of the study were recently published in the Journal of Neuromuscular Diseases.

"In addition to being well tolerated in pediatric patients with DMD, our Phase 1 data demonstrated that edasalonexent (CAT-1004) inhibited NF-κB. This is important because NF-κB is a key link between the loss of dystrophin and disease progression in DMD. This would mean that edasalonexent has the potential to limit disease progression for all patients affected by DMD, regardless of their underlying mutation," explains Joanne Donovan, MD, PhD, Chief Medical Officer of Catabasis Pharmaceuticals, Inc. (Cambridge, MA, USA).

The drug, edasalonexent, is orally administered and that contains two active substances, salicylic acid and the omega-3 fatty acid docosahexaenoic acid (DHA). These two substances separately are inhibitors of NF-kB, but together they provide a more potent inhibition. "This shows that with short-term dosing, edasalonexent can directly reduce the levels of elevated NF-κB in circulating DMD mononuclear cells prior to any changes observable in muscles," notes Dr. Donovan.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 10, 2018
Genetics & Genomics
NOV 10, 2018
Scientists Engineer a Better Way to Direct Evolution
Directed evolution is a Nobel-prize winning technique that has now been simplified and accelerated....
NOV 25, 2018
NOV 25, 2018
Researchers Learn How Hantavirus Infects Cells
First identified in 1993, hantavirus infections can cause dangerous and potentially deadly respiratory infections....
DEC 04, 2018
Drug Discovery
DEC 04, 2018
Drug Combination May Be Effective for Melanoma
Protein kinase inhibitors have been noted to be the most effective class of drugs in the treatment of melanoma—a deadly skin cancer of the melanocyte...
DEC 05, 2018
DEC 05, 2018
Male Contraceptive Gel is in Clinical Trials
Researchers have started a clinical trial involving 420 participants to test the efficacy of a male contraceptive gel....
JAN 06, 2019
Cell & Molecular Biology
JAN 06, 2019
An Inhalable Form of Messenger RNA Might be a New Kind of Therapeutic
Messenger RNA normally carries genetic information from the genome to the ribosome, but researchers want to use it to treat disease....
JAN 15, 2019
JAN 15, 2019
A Possible Key to Severe Flu
By studying the impact that NPY and its receptor Y1R have on influenza in mice, the research group has now discovered that NPY produced in lung phagocytes can aggravate influenza....
Loading Comments...